- Researchers are developing innovative gene therapy approaches to combat Hepatitis B virus (HBV) by targeting and silencing its viral DNA rather than just suppressing symptoms. - Chronic Hepatitis B remains a major global health challenge because existing therapies rarely clear the covalently closed circular DNA (cccDNA) residing in host liver cell nuclei. - Gene therapy techniques, such as gene editing and silencing tools, offer promising avenues for achieving a functional cure for persistent viral infections. - Advances in genetic medicines highlight the intersection of biotechnology, viral pathology, and precision medicine in tackling chronic communicable diseases. - **World Health Organization:** A specialized agency of the United Nations responsible for international public health, setting global health standards, monitoring disease outbreaks, and coordinating emergency responses like vaccination campaigns and pandemic strategies. - **National Institutes of Health:** The primary biomedical research agency of the United States government, conducting and funding extensive scientific studies on human diseases, genetics, and emerging therapeutic interventions. - **U.S. Food and Drug Administration:** A federal regulatory agency of the U.S. government responsible for protecting public health by regulating human drugs, biological products, medical devices, and approving innovative clinical treatments. **Introduction** Recent scientific advancements in gene therapy are exploring novel ways to tackle the hepatitis B virus (HBV) by mutating or silencing its viral DNA. Traditional treatments manage viral loads, but chronic infections persist due to viral reservoirs like cccDNA in liver cells. Emerging genetic interventions offer hope for a permanent or functional cure by directly altering or inactivating the viral genetic material, showcasing the expanding clinical utility of biotechnology in global public health. **Core Issue and Detailed Points** - Researchers are developing innovative gene therapy approaches to combat Hepatitis B virus (HBV) by targeting and silencing its viral DNA rather than just suppressing symptoms. - Chronic Hepatitis B remains a major global health challenge because existing therapies rarely clear the covalently closed circular DNA (cccDNA) residing in host liver cell nuclei. - Gene therapy techniques, such as gene editing and silencing tools, offer promising avenues for achieving a functional cure for persistent viral infections. - Advances in genetic medicines highlight the intersection of biotechnology, viral pathology, and precision medicine in tackling chronic communicable diseases. **Key Statutory Bodies, Acts & Concepts** - **World Health Organization:** A specialized agency of the United Nations responsible for international public health, setting global health standards, monitoring disease outbreaks, and coordinating emergency responses like vaccination campaigns and pandemic strategies. - **National Institutes of Health:** The primary biomedical research agency of the United States government, conducting and funding extensive scientific studies on human diseases, genetics, and emerging therapeutic interventions. - **U.S. Food and Drug Administration:** A federal regulatory agency of the U.S. government responsible for protecting public health by regulating human drugs, biological products, medical devices, and approving innovative clinical treatments.